Last updated on March 2016

Randomized, double-blind, Evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate (110 mg or 150 mg oral b.i.d) versus acetylsalicylic acid (100 mg oral q.d.) in adults with Embolic Stroke of Undetermined Source


Brief description of study

Randomized, double-blind, Evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate (110 mg or 150 mg oral b.i.d) versus acetylsalicylic acid (100 mg oral q.d.) in adults with Embolic Stroke of Undetermined Source

Detailed Study Description

The purpose of this study is to demonstrate the safety and efficacy of DE (110 mg b.i.d. or 150 mg b.i.d. with dosing according to age and renal function), compared to ASA (100 mg once daily) for the prevention of stroke recurrence in adults with stroke of undetermined source. This is an investigational use of the study drugs.

Clinical Study Identifier: TX143004

Find a site near you

Start Over

UNC Rex Healthcare

4420 Lake Boone Trail Raleigh, NC USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.